Please login to the form below
relapsing multiple sclerosis
This page shows the latest relapsing multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb announces positive trial results for treatment of MS
Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis ... for the treatment of adult patients
Latest news
-
Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients
multiple sclerosis (RRMS) who have been treated with Kesimpta (ofatumumab). ... David Martin, chief executive officer, Multiple Sclerosis Trust: “Access to a range of different treatment options is important for people living with MS to manage their
-
SMC approves Biogen’s Vumerity for patients with multiple sclerosis
The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis. ... Biogen’s Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium (SMC) as an oral treatment
-
Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis. ... of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease in
-
Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis
The results showed that after 48 weeks of treatment, tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by magnetic resonance imaging (MRI). ... The data is being presented at the 37th Congress of the European Committee for
-
Biogen’s Vumerity recommended by CHMP in MS
A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis. ... The Committee for Medicinal Products for Human Use (CHMP) has recommended Vumerity (diroximel fumarate) for patients with
More from news
Approximately 1 fully matching, plus 71 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
of B and T cells outside the lymph nodes, to treat relapsing forms of multiple sclerosis. ... phase 3 development to treat relapsing forms of multiple sclerosis.
-
Deal Watch March 2016
Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for plaque psoriasis and relapsing multiple sclerosis.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
When I was diagnosed with relapsing multiple sclerosis (RMS) in 2008, the landscape for disease-modifying therapies (DMTs) looked very different from now.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
